Duality Biotherapeutics (FRA:4ZB) ROE % Adjusted to Book Value: -9.84% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics ROE % Adjusted to Book Value?

Duality Biotherapeutics FRA:4ZB +6.49% 19 ROE % Adjusted to Book Value is -9.84% as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Duality Biotherapeutics's ROE % for the quarter that ended in Jun. 2026 was -94.97%. Duality Biotherapeutics's PB Ratio for the quarter that ended in Jun. 2026 was 9.65. Duality Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -9.84%.

Duality Biotherapeutics ROE % Adjusted to Book Value Related Terms

Duality Biotherapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics ROE % Adjusted to Book Value Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -239.17

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
ROE % Adjusted to Book Value -78.54 -4.12 -9.84

FRA:4ZB vs VRTX, REGN, MRNA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duality Biotherapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's ROE % Adjusted to Book Value falls into.


FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics ROE % Adjusted to Book Value Calculation

Duality Biotherapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-2,270.89% / 9.50
=-239.17%

Duality Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-94.97% / 9.65
=-9.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -9.84% mean?
Duality Biotherapeutics (FRA:4ZB) has a ROE % Adjusted to Book Value of -9.84% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' ROE % Adjusted to Book Value too high?
Duality Biotherapeutics' current ROE % Adjusted to Book Value is -9.84%. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Duality Biotherapeutics' ROE % Adjusted to Book Value of -9.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current ROE % Adjusted to Book Value is -9.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current ROE % Adjusted to Book Value of -9.84%. The current ROE % Adjusted to Book Value is -9.84%. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current ROE % Adjusted to Book Value is -9.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price